Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

ARDX vs NUVB: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ARDX Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 6–4 Matrix Metrics)

ARDX Overall Winner 6-Pillar Tally: ARDX 5 – 1 NUVB Matrix Metrics: ARDX 6 – 4 NUVB

As of Nov 20, 2026, Ardelyx, Inc. (ARDX) is the stronger overall head-to-head candidate over Nuvation Bio Inc. (NUVB) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). ARDX carries a Unified Composite Score of 57.7/100 (HOLD) at $2.99 (18.9x Forward P/E, -7.7% operating margin), whereas NUVB carries 61.0/100 (BUY) at $3.80 (N/M Forward P/E, -61.2% operating margin).

  • Composite vs. Pillar Nuance: While NUVB currently prints a higher short-term Unified Composite Score (61.0/100 BUY vs. ARDX 57.7/100 HOLD), ARDX captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (-7.7% vs. -61.2% operating margin) and revenue trajectory (+15.7% vs. +242.6% YoY).
  • Technical & Structure Timing Caution: ARDX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 43.3); meanwhile NUVB is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ARDX vs NUVB
ARDX NASDAQ Head-to-Head Winner
Ardelyx, Inc.
Pharmaceutical Preparations
$2.99
-2.29% 1D
Market Cap $769.2M
TTM Revenue $468M
Forward P/E 18.9x
Beta / 30D Vol 0.93β · 56% Vol
Unified Composite Score
57.7 / 100 HOLD
Tech 43.0 Fund 54.0 Flow 70.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -8.7%), weak momentum, RSI 43
RSI-14: 43.3 · SMA20: $3.06 · SMA50: $3.22
NUVB NYSE
Nuvation Bio Inc.
Pharmaceutical Preparations
$3.80
-0.26% 1D
Market Cap $1.3B
TTM Revenue $202M
Forward P/E N/M
Beta / 30D Vol 1.52β · 55% Vol
Unified Composite Score
61.0 / 100 BUY
Tech 53.0 Fund 61.0 Flow 67.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -16.7%), weak momentum, RSI 31
RSI-14: 31.3 · SMA20: $4.28 · SMA50: $4.87

6-Pillar Scorecard Institutional Category Breakdown (ARDX 5 – 1 NUVB)

Columns: Metric · ARDX · NUVB
1. Valuation Multiples ARDX
Forward P/E 18.9x N/M
Trailing P/E 52.1x N/M
PEG Ratio N/M N/M
EV / Revenue 2.1x 7.4x
2. Growth & Scale NUVB
Revenue Growth (YoY) +15.7% +242.6%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $468M $202M
Market Cap $769.2M $1.3B
3. Profitability & Quality ARDX
Gross Margin 74.3% 85.8%
Operating Margin -7.7% -61.2%
Net Profit Margin -11.8% -67.4%
Return on Equity (ROE) -34.8% -49.1%
4. Balance Sheet & Cash Flow ARDX
Cash Generation (TTM) -$16M -$108M
Cash Flow Margin -3.4% -53.6%
Net Cash / Leverage $210M Net Debt (1.56x D/E) $146M Net Debt (1.32x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ARDX
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 52.1% (14th %ile) 65.2% (26th %ile)
Put/Call OI Skew 22.00x (Put-Skewed) 0.24x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat ARDX
OpEx & R&D Intensity 82.0% of Rev ($384M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ARDX (6) vs NUVB (4)
Institutional Metric ARDX NUVB Criterion Row Edge
Market Capitalization
Scale
$769.2M $1.3B Larger Scale NUVB
Trailing P/E Ratio
Valuation
52.1x N/M Lower Multiple ARDX
Forward P/E Ratio
Valuation
18.9x N/M Lower Multiple ARDX
Revenue Growth (YoY)
Growth
+15.7% +242.6% Higher Growth NUVB
Operating Margin (TTM)
Profitability
-7.7% -61.2% Higher Margin ARDX
Net Profit Margin
Profitability
-11.8% -67.4% Higher Margin ARDX
Return on Equity (ROE)
Capital Efficiency
-34.8% -49.1% Higher ROE ARDX
52-Week Range Position
Momentum
3% ($3–$8) 2% ($4–$10) Stronger Trend ARDX
Beta / 30D Volatility
Risk Regime
0.93β · 56% Vol 1.52β · 55% Vol Lower Realized Risk NUVB
Unified Institutional Score
Composite Signal
57.7 / 100 (HOLD) 61.0 / 100 (BUY) Higher Composite NUVB
Trailing 12M Revenue (USD)
Operating Scale
$468M $202M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
74.3% 85.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 2.1x EV/Rev N/M PEG · 7.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$16M ($210M Net Debt (1.56x D/E)) -$108M ($146M Net Debt (1.32x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ARDX +12.59 pp
ARDX: -6.56% · NUVB: -19.15%
3M Horizon ARDX +23.74 pp
ARDX: -20.05% · NUVB: -43.79%
6M Horizon NUVB +31.57 pp
ARDX: -51.06% · NUVB: -19.49%
1Y Horizon ARDX +0.53 pp
ARDX: -46.32% · NUVB: -46.85%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period ARDX Revenue NUVB Revenue ARDX Op. Margin NUVB Op. Margin Margin Leader
FY2018 $0M N/A -3488.6% N/A ARDX
FY2019 $10M N/A -1728.1% N/A ARDX
FY2020 $10M N/A -1199.0% N/A ARDX
FY2021 $10M N/A -1528.6% N/A ARDX
FY2022 $50M N/A -122.2% N/A ARDX
FY2023 $120M N/A -50.8% N/A ARDX
FY2024 $330M $10M -8.4% -7527.3% ARDX
FY2025 $410M $60M -10.1% -338.7% ARDX

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ARDX BREAKDOWN
140d in phase · OBV DISTRIBUTION
Current IV 52.1%
IV Percentile 14th %ile
Put/Call OI Skew 22.00x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact ARDX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
NUVB BREAKDOWN
105d in phase · OBV DISTRIBUTION
Current IV 65.2%
IV Percentile 26th %ile
Put/Call OI Skew 0.24x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact NUVB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ARDX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $769.2M market capitalization and -7.7% operating margin.
OpEx & R&D Reinvestment 82.0% of Rev ($384M)
90D Engineering Disclosures 0 Published
NUVB Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.3B market capitalization and -61.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ARDX vs NUVB Key Questions & Quantitative Answers

As of Nov 20, 2026, Ardelyx, Inc. (ARDX) is the stronger overall head-to-head candidate over Nuvation Bio Inc. (NUVB) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). ARDX carries a Unified Composite Score of 57.7/100 (HOLD) at $2.99 (18.9x Forward P/E, -7.7% operating margin), whereas NUVB carries 61.0/100 (BUY) at $3.80 (N/M Forward P/E, -61.2% operating margin). Composite vs. Pillar Nuance: While NUVB currently prints a higher short-term Unified Composite Score (61.0/100 BUY vs. ARDX 57.7/100 HOLD), ARDX captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (-7.7% vs. -61.2% operating margin) and revenue trajectory (+15.7% vs. +242.6% YoY). Technical & Structure Timing Caution: ARDX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 43.3); meanwhile NUVB is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

NUVB leads the Growth & Scale pillar: ARDX posts +15.7% YoY revenue growth and +0.0% YoY earnings growth on $468M TTM revenue (74.3% gross margin, -7.7% operating margin), compared with NUVB at +242.6% YoY revenue growth and +0.0% YoY earnings growth on $202M TTM revenue (85.8% gross margin, -61.2% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), ARDX cumulative revenue shifted +4000.0% while NUVB shifted +500.0%. In operating R&D and SG&A reinvestment, ARDX deploys 82.0% of Rev ($384M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NUVB.

ARDX screens cheaper on headline valuation multiples. ARDX trades at 18.9x Forward P/E, 52.1x Trailing P/E, N/M PEG, and 2.1x EV/Revenue (-3.4% FCF margin), whereas NUVB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 7.4x EV/Revenue (-53.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ARDX (-34.8% ROE) versus NUVB (-49.1% ROE) capital efficiency.

In options market volatility and institutional positioning, ARDX carries 52.1% implied volatility (14th %ile, Compressed (<25th %ile)), a 22.00x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.93β · 56% Vol realized risk). By comparison, NUVB carries 65.2% implied volatility (26th %ile, Balanced (25th–60th %ile)), a 0.24x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.52β · 55% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.